Table 3.

Mutations versus clinical and histopathological parameters.

		TERT n = 15 (%)	P	BRAF n = 13 (%)	P	BAP1 n = 5 (%)	P	NRAS n = 6 (%)	p	PTEN n = 4 (%)	P	c-KIT n= 2 (%)	P	SF3B1 n = 1 (%)	P
Gender			0.26		0.71		1.00		1.00		1.00		1.00		1.00
	Male	6 (40)		6 (46)		3 (60)		3 (50)		3 (75)		1 (50)		1 (100)
	Female	9 (60)		7 (54)		2 (40)		3 (50)		1 (25)		1 (50)		0 (0)
Age			0.91		0.91		0.52		0.32		0.92		0.24		0.50
	<50y	2 (13)		2 (15)		0 (0)		2 (33)		0 (0)		0 (0)		0 (0)
	50–65y	7 (47)		6 (46)		3 (60)		2 (33)		2 (50)		2 (100)		1 (100)
	>65y	6 (40)		5 (38)		2 (40)		2 (33)		2 (50)		0 (0)		0 (0)
Location			0.16		0.85		1.00		1.00		0.59		1.00		0.48
	Bulbar	8 (53)		6 (46)		2 (40)		2 (33)		1 (25)		1 (50)		1 (100)
	Forniceal/ palpebral/ caruncular involvement	5 (33)		6 (46)		2 (40)		2 (33)		2 (50)		1 (50)		0 (0)
Tumor thick-ness			0.67		0.68		1.00		0.63		0.56		0.53		0.31
	Tumor thickness ≤2 mm	5 (33)		3 (23)		1 (20)		2 (33)		2 (50)		1 (50)		1 (100)
	Tumor thickness >2mm	8 (53)		9 (69)		4 (80)		3 (50)		2 (50)		1 (50)		0 (0)
pT status			0.16		0.85		1.00		1.00		0.59		1.00		0.48
	pT1	8 (53)		6 (46)		2 (40)		2 (33)		1 (25)		1 (50)		1 (100)
	pT2	5 (33)		6 (46)		2 (40)		2 (33)		2 (50)		1 (50)		0 (0)
Origin			0.01		1.00		1.00		0.30		1.00		1.00		1.00
	PAM	6 (40)		7 (54)		3 (60)		3 (50)		3 (80)		2 (100)		1 (100)
	Non PAM (nevus/de novo)	7 (47)		3 (23)		1 (20)		3 (50)		1 (25)		0 (0)		0 (0)

P = p-value calculated with either the Pearson’s χ² test or Fisher’s exact test. In bold, the association between the presence of a TERT promoter mutation and origin of the lesion (p-value = 0.01), with most cases (54%) developing either de novo or from a melanocytic nevus. None of the cases showed GNAQ, GNA11, or EIF1AX mutations; therefore, these mutations are not included in the table. pT status = pathological tumor status.